Caan BJ, Cespedes Feliciano EM, Prado CM, et al
Liraglutide was finally approved in 2010 for the treatment of patients with type 2 diabetes unable to regulate their blood sugar with other insulin medications (Gilbert, Rosenthal, Jan 2024)
The Limits Of Todays GLP-1 Boom GLP-1 use has exploded and is expected to grow further as prices fall, and new options emerge, including oral versions such as the Wegovy pill developed by Novo Nordisk
These criteria were established to isolate the impact of GLP-1 prescriptions on study outcomes while controlling for potential confounding factors, with a specific focus on the risk of depression, anxiety, and suicide
Long-term health outcomes of lecanemab in patients with early alzheimers disease using simulation modeling
GLP-1 Probiotic+ ,